Clinical heart failure during pregnancy and delivery in a cohort of female childhood cancer survivors treated with anthracyclines

Elvira C. van Dalen, Helena J.H. van der Pal, Cor van den Bos, Wouter E.M. Kok, Huib N. Caron, Leontien C.M. Kremer

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

36 Citaten (Scopus)

Samenvatting

The cumulative incidence of peripartum anthracycline-induced clinical heart failure (A-CHF) was evaluated in a cohort of 53 childhood cancer survivors who had delivered one or more children. None of them developed peripartum A-CHF (cumulative incidence 0%; 95% confidence interval (CI) 0-5.7%). The mean follow-up time after the first administration of anthracycline therapy was 20.3 years. They received a mean cumulative anthracycline dose of 267 mg/m2. It is worth noticing that even 2 patients with A-CHF before pregnancy did not develop peripartum A-CHF. Since there were no cases of peripartum A-CHF in our cohort, it was not possible to evaluate associated risk factors. In conclusion, this study demonstrates a low risk of developing peripartum A-CHF in childhood cancer survivors. However, more cohort studies with adequate power and long-term follow-up are needed to reliably evaluate the cumulative incidence of peripartum anthracycline-induced cardiotoxicity (both clinical and asymptomatic) and associated risk factors.

Originele taal-2Engels
Pagina's (van-tot)2549-2553
Aantal pagina's5
TijdschriftEuropean Journal of Cancer
Volume42
Nummer van het tijdschrift15
DOI's
StatusGepubliceerd - okt. 2006
Extern gepubliceerdJa

Vingerafdruk

Duik in de onderzoeksthema's van 'Clinical heart failure during pregnancy and delivery in a cohort of female childhood cancer survivors treated with anthracyclines'. Samen vormen ze een unieke vingerafdruk.

Citeer dit